Gain Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Gain Therapeutics, Inc. Overview

Gain Therapeutics is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. With its Magellan drug discovery platform, the company integrates AI, physics-based methods, and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 5 trillion compounds in less than 3 months. Its lead drug candidate, GT-02287 (now called rexaceract), is in Phase 1b evaluation for Parkinson's disease with potential in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease.

Strategic Profile

The company's proprietary SEE-Tx target identification platform identifies and optimizes previously untargeted allosteric binding sites, enabling development of new treatments for disorders characterized by protein misfolding. Gain targets a capital-efficient drug discovery approach using computational methods rather than traditional screening, positioning it to advance multiple pipeline programs across CNS, lysosomal, metabolic, and oncology indications.

Competitive Landscape

Direct competitors in neurodegenerative/allosteric space include Polaryx Therapeutics, Capsida Biotherapeutics, Neurometa Therapeutics, Voyager Therapeutics, and Regenxbio. Gain differentiates through its computational Magellan platform targeting allosteric sites, but faces competition from larger biopharmaceutical firms also advancing Parkinson's therapeutics.

Industry Context

Gain Therapeutics, Inc. operates in Neurology Drugs.

Key facts

Founded: 2017 · Headquarters: Bethesda, Maryland, US · Market cap: $81.5M (as of July 2, 2026)